Information

This site is only for use by healthcare professionals. By continuing to view this site you are confirming that you are a healthcare professional.

Confirm

Key Opinions in Medicine

  • Register
  • Login
Skip to content
  • Home
  • Issues
    • Allergy & Immunology
    • Cardiology
    • Conference
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes & Endocrinology
    • Gastroenterology
    • General Medicine
    • Haematology
    • Hepatology
    • Infectious Diseases
    • Metabolic Disorders
    • Neurology
    • Nursing
    • Obstetrics & Gynaecology
    • Oncology
    • Paediatrics
    • Psychiatry
    • Rheumatology
    • Surgery Insights
    • Urology
  • About
  • Contact
  • Register
  • Login

Figure 2

Published May 4, 2016 at 563 × 423 in Choosing field-directed therapy in management of actinic keratosis: the role of topical imiquimod 3.75%.
← Previous Next →

Rapid clearance of AK with imiquimod 3.75% over two treatment cycles is followed by a sustained period free of lesions. Note the increase in lesion count up to Lmax as treatment reveals subclinical lesions26

Popular Issues

Konkurrenz für den Therapiestandard

MOVICOL® (PEG3350 plus electrolytes): 20 years of evidence-based use

Register

Register

Sign up for free access to Wiley’s Key Opinions in Medicine to keep up to date with latest trends and key developments within your specialty area.

Share

Copyright © 2000-2026 by John Wiley & Sons, Inc., or related companies. All rights reserved.
Review our privacy policy. Cookie Preferences.
Web design and marketing agency Leamington Spa